Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Life Sciences Tools & Services2.30%+0.26 ppPharmaceuticals4.65%-0.21 ppHealth Care Equipment3.22%-0.14 ppHealth Care Services0.79%-0.11 ppHealth Care Distributors0.27%-0.05 ppBiotechnology2.37%+0.02 ppHealth Care Supplies0.29%+0.02 ppHealth Care Facilities0.24%+0.02 ppManaged Health Care2.07%+0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.37%
Industry change · 12M
+0.02 pp
Biotechnology · contribution
+0.023 pp
Company participation
25%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Nov 2021 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $142.9bn | 0.483% | -0.026 pp | +0.483 pp | +130.7% | Yes |
| Amgen → AMGN | United States | $112.0bn | 0.378% | -0.050 pp | -0.171 pp | -7.7% | No |
| AbbVie → ABBV | United States | $203.8bn | 0.689% | -0.025 pp | -0.096 pp | +15.5% | No |
| Vertex Pharmaceuticals → VRTX | United States | $47.5bn | 0.161% | -0.013 pp | -0.091 pp | -17.9% | No |
| Biogen → BIIB | United States | $34.6bn | 0.117% | -0.052 pp | -0.040 pp | -1.8% | No |
| Gilead Sciences → GILD | United States | $86.5bn | 0.292% | -0.013 pp | -0.031 pp | +18.6% | No |
| Incyte → INCY | United States | $15.0bn | 0.051% | -0.006 pp | -0.028 pp | -19.9% | No |
| Regeneron Pharmaceuticals → REGN | United States | $59.8bn | 0.202% | -0.010 pp | -0.004 pp | +23.4% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.